SUBSCRIBE
SUBSCRIBE

Lori Ellis

Head of Insights

Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.

IN PARTNERSHIP WITH IQVIA
AI’s Role in Decoding the FDA’s New Regulatory Communications
In this episode of Denatured, presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.
June 5, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH IQVIA
How Target Product Profiles Guide the Industry Through Uncertain Times
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the importance of target product profiles, particularly when navigating funding challenges, with Ian Fisher, head of development analytics.
May 22, 2025
 · 
1 min read
 · 
Lori Ellis
US Measles Outbreak and Increase in infection cases concept as a rising deadly outbreak disease and viral illness as a contagious chickenpox or a skin rash.
Policy
The Memory Gap: How Forgotten Diseases Are Making a Dangerous Comeback
In a year when eradicated diseases are on the uptick in America, how will American children survive RFK Jr.’s vaccine scrutiny and inconsistency? Two experts call on pharma and regulatory bodies to rebuild trust.
May 19, 2025
 · 
6 min read
 · 
Lori Ellis
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
In this episode of Denatured BioSpace’s head of insights Lori Ellis discusses the public health consequences of vaccine hesitancy and the critical distinction between skepticism and cynicism with Paul Offit, MD, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia.
May 8, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH DIA
Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses how collaboration and investment shape the the future of women’s health with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
April 24, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH DIA
Breaking Down Barriers: The Nuanced Approach to Women’s Representation in Medical Research
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
April 10, 2025
 · 
1 min read
 · 
Lori Ellis
IN PARTNERSHIP WITH DIA
Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the evolution of women’s inclusion in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
March 27, 2025
 · 
1 min read
 · 
Lori Ellis
Business
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of inclusion and exclusion criteria of clinical trial patients, and reflect on current investment approaches around women’s health.
March 13, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Building Patient Trust Amid an Environment of Distrust
While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare.
February 28, 2025
 · 
1 min read
 · 
Lori Ellis
Business
Money Meets Medicine: A Disruptor’s Guide to Life Sciences Investment
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss life sciences investment and the potential for disruption.
February 27, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Beyond Dr. Google: The Roles of Industry and AI in Fighting Misinformation and Fueling Patient Empowerment
As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient empowerment is paramount.
February 27, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Diversity at the Forefront: Life Sciences Industry Champions Inclusive Representation
The industry remains unwavering in the commitment to increased clinical trial accessibility and representation.
February 25, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Site Survival: Why Clinical Research Sites Need a Lifeline
Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving patient trust and the overall viability of clinical trials.
February 19, 2025
 · 
1 min read
 · 
Lori Ellis
Drug Development
Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
February 17, 2025
 · 
1 min read
 · 
Lori Ellis
Load More